26 May - 4 min read

Board and committee succession

Board and committee succession

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company”, or the “Group”)

26 May 2021

Board and committee succession

Mediclinic, a leading international private healthcare services group, announces that on 25 May 2021, Messrs
Alan Grieve and Trevor Petersen, both independent non-executive directors, informed the Board of their
intention to retire as directors of the Company upon the conclusion of their second three-year term of
appointment on 14 February 2022. The Board is in the process of actively recruiting two new independent non-
executive directors and the Company will make further announcements when it is in a position to confirm the

The Company is mindful that both Messrs Grieve and Petersen were appointed as directors of Mediclinic
International Limited (a predecessor company to Mediclinic International plc) on 13 September 2012 and that
despite the Board’s views to the contrary, the length of their tenure may, under the UK Corporate Governance
Code, be viewed as impairing their independence. In view of this, and in the interests of continuity and
significant knowledge of the company, Messrs Grieve and Petersen will continue to serve on the Board in a
non-independent capacity from 13 September 2021 until 14 February 2022.

In addition, with effect from 13 September 2021:
- Dr Felicity Harvey will succeed Mr Grieve as Senior Independent Director of the Company,
- Mr Tom Singer will succeed Mr Grieve as Chair of the Audit & Risk Committee, and
- Mr Steve Weiner will succeed Mr Petersen as Chair of the Remuneration Committee.

Messrs Grieve and Petersen will step down f rom all Board committees with effect f rom 13 September 2021.

Mediclinic's Chair, Dame Inga Beale commented:
"On behalf of the Board, I would like to thank Alan and Trevor for their commitment and valued contributions
to the Board and the Group over many years. We are using the opportunity afforded by their retirements to
further refresh and strengthen the Board. I wholeheartedly welcome Felicity’s appointment as Senior
Independent Director, Tom’s appointment as Chair of the Audit and Risk Committee and Steve becoming Chair
of the Remuneration Committee".

This announcement is made in accordance with the requirement of LR 9.6.11.

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with
divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates (“UAE”).

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of
care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare
services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 31 March 2021, Mediclinic comprised 74 hospitals, five sub-acute hospitals, two mental health facilities,
18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and f our day case clinics in
Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals
(three of which in Namibia), five sub -acute hospitals, two mental health facilities and 12 day case clinics (four
of which operated by Intercare) across South Africa, and around 8 600 inpatient beds; and Mediclinic Middle
East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient
beds in the UAE. In addition, under management contracts, Mediclinic Middle East operates one hospital in
Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in mid -2022.

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.

For further information, please contact:

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd                                                    

Date: 26-05-2021 08:05:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

More from Mediclinic International plc

Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more.

By joining Listcorp you agree to our Terms & Conditions and Privacy Policy

Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Mediclinic International plc (JSE:MEI) when you join Listcorp.